ReviewCureus2021
Lacosamide-Related Arrhythmias: A Systematic Analysis and Review of the Literature.
Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers.Pflugers Archiv : European journal of physiology · 2024Pooled it
- Risk assessment of arrhythmias related to three antiseizure medications: a systematic review and single-arm meta-analysis.Frontiers in neurology · 2024Pooled it
- Choice of antiseizure medications and associated outcomes in Medicare beneficiaries after acute ischemic stroke.Epilepsia · 2025Article
- Development and Validation of a Model to Predict Secondary Arrhythmia in Patients With Epilepsy.CNS neuroscience & therapeutics · 2025Article
- Focused ultrasound combined with drug-loaded microbubbles suppresses ictal spikes in kainic acid-induced epileptic animals.Ultrasonics sonochemistry · 2025Article
- Differences in patterns of outpatient epilepsy-specific medication initiation after acute ischemic stroke in the Medicare population.Epilepsia · 2025Observational
- Role of Medication Reconciliation in Managing Bradycardia: A Rare Cause of Medication-Induced Sinus Bradycardia.Cureus · 2025Article
- Cardiovascular Effects of Antiseizure Medications for Epilepsy.CNS drugs · 2025Review
- Choice of Epilepsy Anti-Seizure Medications and Associated Outcomes in Medicare Beneficiaries.medRxiv : the preprint server for health sciences · 2025Article
- Management recommendations to reduce cardiac risk in chronic epilepsy.Epilepsy & behavior reports · 2025Review
- Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System.Frontiers in neurology · 2025Article
- [Reversibility of a critical intraventricular conduction delay under flecainide and lacosamide by sodium bicarbonate].Innere Medizin (Heidelberg, Germany) · 2024Article
- Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database.Scientific reports · 2024Article
- Lacosamide Intoxication-induced Wide QRS Tachycardia Successfully Treated with Veno-arterial Extracorporeal Membrane Oxygenation.Internal medicine (Tokyo, Japan) · 2023Article
- Evaluation of Cardiovascular Concerns of Intravenous Lacosamide Therapy in Epilepsy Patients.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lacosamide (LCM) is a new antiepileptic drug used as an adjunctive treatment for partial seizures with and without secondary generalization. One of the modes of action is the enhancement of slow inactivation of voltage-gated sodium channels. Experimental studies and clinical trials suggest that LCM acts upon both neurons and the heart and may increase the risk of cardiac arrhythmias. A systematic review was conducted to investigate characteristics of arrhythmias related to the use of LCM for the treatment of seizures. The search terms "lacosamide", "arrhythmias", "AV block", "atrial fibrillations/flutter", "cardiac conductions defects", "ventricular tachycardia", "ventricular fibrillation were used. Case reports and retrospective studies were gathered by searching Medline/PubMed, Google Scholar, CINAHL (Cumulative Index to Nursing and Allied Health Literature), Cochrane CENTRAL (Cochrane Central Register of Controlled Trials), and Web of Science databases. Seventeen articles were selected for review. Ventricular tachycardia was the most reported LCM related arrhythmia (29.4%), followed by new-onset atrial fibrillation (17.6%), complete heart block (17.6%), Mobitz type 1 Atrio-ventricular block (11.8%), sinus pauses (11.8%), pulseless electrical activity (5.9%) and widening QRS complex (5.9%). Further research and clinical trials are needed to explore the etiopathogenesis and causative relationship between the use of LCM and arrhythmias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.